In preclinical experiments, the combination of BEZ235 and enzalutamide (an androgen-receptor antagonist) demonstrated near-complete tumor regression in a PTEN-deficient murine model and in human prostate cancer xenografts.5 A phase Ib proof-of-concept trial of BEZ235 or buparlisib in combination with abiraterone acetate is currently enrolling patients with CRPC after progression on abiraterone acetate (NCT01634061). Here, PTEN is linked to prostate carcinoma.